Stock Movers: Lennar, Verve Therapeutics, Sunrun, and T-Mobile Discussed
Bloomberg PodcastsJune 17, 20254 min518 views
8 connectionsΒ·14 entities in this videoβLennar's Performance and Outlook
- π Lennar (LEN) shares edged higher despite missing new orders outlook, buoyed by better-than-expected gross margins.
- π‘ Analysts noted that Lennar's gross margin percentage came in better than feared, with the guide for a flat quarter-on-quarter margin also surprising positively.
- π Despite the positive margin news, Lennar shares have fallen about 16% year-to-date, with affordability challenges and economic uncertainty impacting consumer confidence.
- β οΈ The homebuilder has relied on mortgage rate buydowns to drive sales but faces competition from the existing home market, with loan costs hovering near 7%.
T-Mobile and SoftBank's Strategic Sale
- π± T-Mobile (TMUS) shares slid after SoftBank raised approximately $4.8 billion by selling 21.5 million shares at a discount.
- π€ This significant share sale is intended to fund SoftBank's substantial investments in artificial intelligence, including a planned $30 billion investment in OpenAI and global data center infrastructure.
- π The sale represents the largest US share sale since February, highlighting SoftBank's strategic move to finance its AI ambitions.
Solar Industry Challenges
- βοΈ Sunrun (RUN) shares are sinking following a downgrade by KeyBanc Capital Markets to 'underweight'.
- π A new tax bill proposed by Senate Republicans includes an end to tax credits for wind and solar in 2028, earlier than for other energy sources.
- π Analysts suggest this will significantly hurt the solar industry, impacting companies that lease rooftop solar systems and homeowners who purchase them.
Verve Therapeutics Acquisition by Eli Lilly
- 𧬠Verve Therapeutics (VERV) shares are soaring on a report that Eli Lilly is in advanced talks to acquire the gene-editing startup for up to $1.3 billion.
- π° The deal reportedly includes an almost $1 billion upfront payment and an additional $300 million tied to clinical milestones.
- π Eli Lilly shares experienced a slight dip on the news of the potential acquisition.
Knowledge graph14 entities Β· 8 connections
How they connect
An interactive map of every person, idea, and reference from this conversation. Hover to trace connections, click to explore.
Hover Β· drag to explore
14 entities
Chapters3 moments
Key Moments
Transcript18 segments
Full Transcript
Topics15 themes
Whatβs Discussed
Stock MoversLennarVerve TherapeuticsSunrunT-MobileGross MarginsNew Orders OutlookMortgage RatesSoftBankArtificial IntelligenceOpenAISolar IndustryTax CreditsEli LillyGene Editing
Smart Objects14 Β· 8 links
CompaniesΒ· 10
ConceptsΒ· 4